Skip to main content

The Need of New Drug for Tuberculosis (Need of RtmB Inhibitors to Back Aminoglycoside in Market)

Pharma courses


pharma courses


Submitted by admin on 1 December 2012

TB bacteria have developed many different ways to protect themselves from attack by aminoglycoside and other antibiotics.

Ribosomal RNA methyl transferase B (RmtB) is one of the new enzyme developed by TB bacteria to make the modification in 16 s rRNA in 30s ribosomal subunit (target of aminoglycoside).

So, Inhibition of this new developed enzyme (RmtB) is therefore an important challenge for the development of a new effective therapy for tuberculosis

Record your opinion on the above link.

Search this website